<DOC>
	<DOC>NCT01817283</DOC>
	<brief_summary>This study is a prospective, multicenter, randomized, placebo-controlled clinical trial, to evaluate impact of Triptolide wilfordii on T cell immune activation and inflammation biomarkers in HIV-infected immunological non-responders.</brief_summary>
	<brief_title>Impact on T Cell Immune Activation and Inflammation of Triptolide Woldifii in HIV-infected Immunological Non-responders</brief_title>
	<detailed_description>About 120 patients will be recruited from 4 HIV/AIDS clinical centers in China and randomized 1:1 into intervention group and placebo-controlled group. Triptolide wilfordii (20mg tid po) would be given to invention group for 24 weeks. T cell activation and inflammation biomarkers including CD8+HLA-DR+CD38+, IL-6, D-Dimer and high-sensitivity C-reactive protein (hsCRP), protein degradation-1 (PD-1), Ki67 ,soluble CD14 and CD163, PD-1, CCR5 and CD57 would be tested. Patients in placebo-controlled group will change to take Triptolide wilfordii (20mg tid po) for another 24 weeks. All patients will be followed up till 48 weeks. We hypothesis that Triptolide wilfordii might reduce immune activation and inflammation of HIV immunological non-responders and increase CD4 T cell count, which provides a new strategy for treatment of HIV-infected immunological non-responders.</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Triptolide</mesh_term>
	<criteria>Continuous antiretroviral therapy &gt; 24 months ， and consistent HIVRNA&lt; 40 copies/mL more than 12 months ; 1865 years old; Male or female; Good adherence and promise to followup; Inform Consent signed; CD4 T cells less than 250/ul . Active opportunistic infection (not stable within 4 weeks 2 weeks ) or AIDSrelated carcinoma; hemoglobin (HGB) &lt; 9 g/dl 、 white blood cell (WBC) &lt; 2000/ul 、 granulin (GRN) &lt; 1000 /ul 、 platelet (PLT) &lt; 75000 /ul 、 Cr &gt;1.5x ULN 、 ALT or AST or alkaline phosphatase (ALP) &gt;3x upper limit of normal (ULN) 、 total bilirubin (TBIL) &gt;2x ULN 、 creatine kinase (CK) &gt; 2x ULN; Pregnant or breastfeeding woman or woman with pregnancy plan; Active druguser; Severe neurological defects; Active alcohol abuse; Severe gastrointestinal ulcer . Endstage disease such as cirrhosis, chronic obstructive pulmonary disease, congestive heart failure, recent myocardial ischemia,tumor, etc Those who are undertaking steroids, immunomodulator, antiinflammatory agents</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>HIV-infected immunological non-responders</keyword>
	<keyword>Triptolide</keyword>
	<keyword>immune activation</keyword>
	<keyword>inflammation</keyword>
	<keyword>CD4 T cell</keyword>
</DOC>